Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy
Christophe Hézode,1 Paul Kwo,2 Jan Sperl,3 Peggy Hwang,4 Jianmin Long,4 Rohit Talwani,4 Michael N Robertson,4 Barbara A Haber4 1Service d’Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France; 2Division of Gastroenterology/Hepatology, Department of Medicin...
Saved in:
Main Authors: | Hézode C (Author), Kwo P (Author), Sperl J (Author), Hwang P (Author), Long J (Author), Talwani R (Author), Robertson MN (Author), Haber BA (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
P64 Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir
by: N. Reau, et al.
Published: (2017) -
Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
by: Morikawa K, et al.
Published: (2018) -
Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
by: Jinyu Liu, et al.
Published: (2022) -
Spotlight on grazoprevir—elbasvir once-daily combination and its potential in the treatment of hepatitis C
by: Suraweera D, et al.
Published: (2016) -
Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam
by: Chizoba Nwankwo, et al.
Published: (2019)